Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-683-1880
Debt
Current Ratio2.10
Quick Ratio2.10
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book0.72
Profitability
Net Income$-28,300,000.00
Net MarginsN/A
Return on Assets-56.15%
Miscellaneous
Employees21
OptionableOptionable
Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics Inc (NASDAQ:AGRX) posted its earnings results on Thursday, November, 1st. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. View Agile Therapeutics' Earnings History.
When is Agile Therapeutics' next earnings date?
What price target have analysts set for AGRX?
4 brokers have issued twelve-month target prices for Agile Therapeutics' shares. Their predictions range from $3.00 to $4.00. On average, they anticipate Agile Therapeutics' stock price to reach $3.3333 in the next twelve months. This suggests a possible upside of 335.7% from the stock's current price. View Analyst Price Targets for Agile Therapeutics.
What is the consensus analysts' recommendation for Agile Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics.
Has Agile Therapeutics been receiving favorable news coverage?
Headlines about AGRX stock have trended somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agile Therapeutics earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Are investors shorting Agile Therapeutics?
Agile Therapeutics saw a decrease in short interest during the month of December. As of December 14th, there was short interest totalling 1,294,868 shares, a decrease of 27.0% from the November 30th total of 1,772,743 shares. Based on an average daily trading volume, of 299,140 shares, the short-interest ratio is presently 4.3 days. Approximately 5.5% of the shares of the company are sold short. View Agile Therapeutics' Current Options Chain.
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include Checkpoint Therapeutics (CKPT), Eton Pharmaceuticals (ETON), Catalyst Biosciences (CBIO), DURECT (DRRX), Vernalis (VNLPY), Cumberland Pharmaceuticals (CPIX), Evofem Biosciences (EVFM), BioXcel Therapeutics (BTAI), Teligent (TLGT), Mustang Bio (MBIO), PhaseBio Pharmaceuticals (PHAS), Acasti Pharma (ACST), Humanigen (HGEN), Tiziana Life Sciences (TLSA) and Ovid Therapeutics (OVID).
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Mr. Alfred F. Altomari, Chairman & CEO (Age 60)
- Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)
- Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)
- Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)
- Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62)
How do I buy shares of Agile Therapeutics?
Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of AGRX stock can currently be purchased for approximately $0.7650.
How big of a company is Agile Therapeutics?
Agile Therapeutics has a market capitalization of $26.82 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe.
What is Agile Therapeutics' official website?
How can I contact Agile Therapeutics?
Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]
MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
